2-phospho-D-gluconic acid | 17181-77-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-phospho-D-gluconic acid
• 英文别名: D-Gluconsaeure-2-phosphat；2-Phospho-D-gluconsaeure；phosphogluconate；Phosphogluconic acid；(2R,3S,4R,5R)-3,4,5,6-tetrahydroxy-2-phosphonooxyhexanoic acid
• CAS: 17181-77-0
• 化学式: C₆H₁₃O₁₀P
• 分子量: 276.137
• InChiKey: NFBQIWJDUKFHJP-SQOUGZDYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  185
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  glucose 1-phosphate 在 溴 、 barium carbonate 作用下， 生成 2-phospho-D-gluconic acid
  参考文献：
  名称：

  Courtois; Ramet, Bulletin de la Societe de Chimie Biologique, 1945, vol. 27, p. 614

  摘要：

  DOI：

文献信息

• Kyberdrug as autovaccines with immune-regulating effects
  申请人：——

  公开号：US20020155997A1

  公开（公告）日：2002-10-24

  The present invention is directed to a “Kyberdrug” and to a pharmaceutical composition containing an effective amount of the Kyberdrug and a pharmaceutical carrier therefor, and its medicinal use as an immune modulating drug exhibiting autovaccine-like activities.

  本发明涉及一种“Kyberdrug”，以及含有Kyberdrug有效量和药用载体的制药组合物，以及其作为一种免疫调节药物展示自身疫苗样活性的药用。
• Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
  申请人：Roche Diagnostics GmbH

  公开号：EP2899544A1

  公开（公告）日：2015-07-29

  The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The at least one marker is selected from the group consisting of creatinine, urea, sodium, glucose, HbAlc (glycated hemoglobin), hemoglobin, and hematocrit. Further markers are disclosed.

  本发明涉及一种确定符合强化心衰治疗条件的患者的方法。此外，本发明还涉及一种优化 BNP 型肽引导的心衰治疗的方法。这些方法基于对接受 BNP 型肽引导的心衰治疗的心衰患者样本中至少一种标记物水平的测量。本发明还设想了适用于实施本发明的试剂盒和设备。至少一种标记物选自肌酐、尿素、钠、葡萄糖、HbAlc（糖化血红蛋白）、血红蛋白和血细胞比容组成的组。本发明还公开了更多的标记物。
• BIOMARKERS FOR RISK ASSESSMENT AND TREATMENT MONITORING IN HEART FAILURE PATIENTS GUIDED BY NATRIURETIC PEPTIDES
  申请人：Roche Diagnostics GmbH

  公开号：EP3470848A2

  公开（公告）日：2019-04-17

  The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention.

  本发明涉及一种确定符合强化心衰治疗条件的患者的方法。此外，本发明还涉及一种优化 BNP 型肽引导的心衰治疗的方法。这些方法基于对接受 BNP 型肽引导的心衰治疗的心衰患者样本中至少一种标记物水平的测量。本发明还设想了适用于实施本发明的试剂盒和设备。
• Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
  申请人：Roche Diagnostics Operations, Inc.

  公开号：US10684291B2

  公开（公告）日：2020-06-16

  The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

  本说明涉及一种确定符合强化心衰治疗条件的患者的方法。此外，还涉及一种优化 B 型利钠肽 (BNP) 和/或 N 端亲 B 型利钠肽 (NT-proBNP) 型肽引导的心衰治疗的方法。这些方法基于对接受 B 型利钠肽 (BNP) 和/或 N 端原 B 型利钠肽 (NT-proBNP) 型肽指导的心衰治疗的心衰患者样本中至少一种标记物水平的测量。进一步描述了适用于实施所述方法的试剂盒和设备。
• Courtois, 1943, vol. 8, p. 111
  作者：Courtois

  DOI：——

  日期：——